Skin cancer in skin of color transplant patients
Pritchett E. Skin cancer in skin of color transplant patients. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 2017; 76(6):AB236-AB236.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Objectives: 1. Use UNOS/OPTN to establish a cohort of HFHS patients who received heart, lung, liver, pancreas or kidney organ transplants between January 1, 1990 and December 31, 2011 2. Explore racial differences in histologically-confirmed skin cancer for OTRs: calculate the incidence of skin cancer by race; calculate the cumulative incidence of skin cancer in the cohort using person-years at risk; compare, by race, the rates of skin cancer for OTRs in our cohort to that of the general population to determine if the difference in rates observed by race in the general population is similar to the difference in rates by race among OTRs. The racial difference in skin cancer between whites and nonwhites in our cohort of OTRs will be of a lesser magnitude (eg, <70) than that reported for the general population. 3. Explore racial differences in indicators of severity/poor outcomes for squamous cell carcinoma, including number of lesions, recurrence of cancer, metastasis and death. H2: Among transplant patients with SCC, nonwhites will have worse outcomes, indicated by number of cancers, recurrence of cancer, metastasis, and death. Organ transplant patients are required to take lifelong immunosuppressant medications, resulting in a higher risk of developing skin cancer. In addition, patients with skin of color who develop skin cancer often have worse outcomes (ie, spread of cancer to other organs and death) when compared to white patients with a similar diagnosis. These differences in outcomes are likely due to delays in skin cancer diagnosis and treatment. This chart review aims to study three types of skin cancer (basal cell, squamous cell, and melanoma skin cancer) in a group of individuals who are both non-white and have received organ transplants. The goal is to explore racial differences in skin cancer outcomes, including the number of skin cancers, spread of cancer to other organs, and death from skin cancer. Information was obtained from a national database, United Network of Organ Sharing (UNOS)/Organ Procurement and Transplantation Network (OPTN) and from the Henry Ford Health System electronic medical record. Based on preliminary findings, we expect the nonwhite organ transplant patients to have worse outcomes. References to be provided once accepted.